Abstract
The use of laser and light devices for melasma is based on its effects on several pathogenetic pathways.
-
Pigmentation in melasma is due to deposition of melanin in the keratinocytes and dermis, and the basis of laser and light treatment is fragmentation and removal of melanin.
-
Melanin has a broad absorption spectrum stretching from wavelengths of 500–1064 nm, allowing a variety of lasers and light sources to be used for fragmenting the melanin pigment.
-
Melanosomes have very short thermal relaxation time, in the range of 50–500 ns, and hence lasers and light devices with short pulse duration (in nanosecond and possibly picosecond domain) are the preferred devices (Q-switched lasers).
-
Longer wavelength lasers and light devices penetrate deeper and are required to target dermal pigment – hence longer wavelength lasers are preferred to treat melasma than shorter wavelength lasers which can target epidermal pigment only; however, longer wavelength lasers may cause more epidermo-dermal basement damage and lead to post-inflammatory hyperpigmentation.
-
To achieve favorable outcome, a maintenance treatment coupled with other modalities (topicals) should be used.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035–9.
Tse Y, Levine VJ, McClain SA, Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol. 1994;20:795–800.
Alster TS, Lupton JR. Laser therapy for cutaneous hyperpigmentation and pigmented lesions. Dermatol Ther. 2001;14:46–54.
Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by QS ruby laser. J Dermatol Surg Oncol. 1994;20(9):592–7.
Manaloto RMP, Alster T. Erbium: YAG laser resurfacing for refractory melasma. Dermatol Surg. 1999;25:121–3.
Nouri K, Bowes L, Chartier T, Romagosa R, Spencer JM. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched Alexandrite laser: a pilot study. Dermatol Surg. 1999;25:494–7.
Angsurarangsee S, Polnikorn N. Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: Split face design. Dermatol Surg. 2003;29:59–64.
Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426–38.
Rahman Z, Alam M, Dover JS. Fractional laser treatment for pigmentation and texture improvement. Skin Therapy Lett. 2006;11:7–11.
Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg Med. 2006;38(2):142–9.
Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg. 2005;31:1645–50.
Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: ablative vs non-ablative. Br J Dermatol. 2012;166:1160–9.
Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med. 2008;40:134–8.
Lee HS, Won CH, Lee DH, An JS, Chang HW, Lee JH, et al. Treatment of melasma in Asian skin using a fractional 1,550-nm laser: an open clinical study. Dermatol Surg. 2009;35(10):1499–504.
Wind BS, Kroon MW, Meesters AA, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, et al. Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med. 2010;42(7):607–12.
Kroon MW, Wind BS, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol. 2011;64(3):516–23.
Jang YH, Park JY, Park YJ, Kang HY. Changes in melanin and melanocytes in mottled hypopigmentation after low-fluence 1,064-nm Q-switched Nd:YAG laser treatment for melasma. Ann Derm. 2015;27(3):341.
Polnikorn N. Rx of refractory dermal melasma with QS Nd:YAG laser: 2 case reports. J Cosmet Laser Ther. 2008;10:167–73.
Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol. 2009;34:e847–50.
Jeong SY, Shin JB, Yeo UC, Kim WS, Kim IH. Low-fluence QS Nd:YAG laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2010;6:909–18.
Choi M, Choi JW, Lee SY, Choi SY, Park HJ, Park KC, et al. Low-dose 1064-nm Q-switched Nd:YAG laser for the Rx of melasma. Dermatol Treat. 2010;21:224–8.
Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched Nd:YAG (1,064 nm) Laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010;36(1):76–87.
Shek SY, Yeung CK, Chan HH. A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med. 2010;42(8):712–9.
Kou S, Yasumura K, Satake T, Maegawa J. Influence of the frequency of laser toning for melasma on occurrence of leukoderma and its early detection by ultraviolet imaging. Lasers Surg Med. 2015;47(2):161–7.
Jang YH, Park JY, Park YJ, Kang HY. Changes in melanin and melanocytes in mottled hypopigmentation after low-fluence 1,064-nm Q-switched Nd:YAG laser treatment for melasma. Ann Derm. 2015;27(3):340–2.
Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg. 2004;30:1196–200.
Li YH, Chen ZS, Wei HS, Wu Y, Liu M, Xu YY, et al. Efficiency of and safety of Intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34:1–9.
Bae MI, Park JM, Jeong KH, Lee MH, Shin MK. Effectiveness of low-fluence and short-pulse intense pulsed light in the treatment of melasma: a randomized study. J Cosmet Laser Ther. 2015;17(6):292–5.
Jun WJ, Lee SM, Han JS, Lee SH, Chang SY, Haw S, et al. A prospective, split-face, randomized study of the efficacy and safety of a novel fractionated intense pulsed light treatment for melasma in Asians. J Cosmet Laser Ther. 2015;17(5):259–66.
Vachiramon V, Sirithanabadeekul P, Sahawatwong S. Low-fluence Q-switched Nd:YAG 1064-nm laser and intense pulsed light for the treatment of melasma. J Eur Acad Dermatol Venereol. 2015;29(7):1339–46.
Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Derm Sci. 2007;46:111–6.
Passeron T. Melasma pathogenesis and influencing factors: an overview of the latest research. J Eur Acad Dermatol Venereol. 2013;27(S1):5–6.
Passeron T, Fontas E, Kang HY, Bahadoran P, Lacour JP, Ortonne JP. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study. Arch Dermatol. 2011;147(9):1106–8.
Passeron T. Long-lasting effect of vascular targeted therapy of melasma. J Am Acad Dermatol. 2013;69(3):e141–2.
Lee HI, Lim YY, Kim BJ, Kim MN, Min HJ, Hwang JH, Song KY. Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511) for treatment of melasma in Asian patients. Dermatol Surg. 2010;36:885–93.
Eimpunth S, Wanitphadeedecha R, Triwongwaranat D, Varothai S, Manuskiatti W. Therapeutic outcome of melasma treatment by dual-wavelength (511 and 578 nm) laser in patients with skin phototypes III-V. Clin Exp Dermatol. 2014;39(3):292–7.
Ghorbel HH, Boukari F, Fontas E, Montaudié H, Bahadoran P, Lacour JP, Passeron T. Copper bromide laser vs triple-combination cream for the treatment of melasma: a randomized clinical trial. JAMA Dermatol. 2015;151(7):791–2.
GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, Grade Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
GRADE Working Group. Rating quality of evidence and strength of recommendations: What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer India
About this chapter
Cite this chapter
Goh, C.L. (2017). The Role of Lasers and Light Devices for the Treatment of Melasma. In: Handog, E., Enriquez-Macarayo, M. (eds) Melasma and Vitiligo in Brown Skin. Springer, New Delhi. https://doi.org/10.1007/978-81-322-3664-1_16
Download citation
DOI: https://doi.org/10.1007/978-81-322-3664-1_16
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-3662-7
Online ISBN: 978-81-322-3664-1
eBook Packages: MedicineMedicine (R0)